Haebaru

This research investigates the effects of hypothermia versus normothermia on patients who have undergone extracorporeal cardiopulmonary resuscitation ECPR following out-of-hospital cardiac arrest OHCA. The trial aims to compare mortality risks, neurological outcomes, and adverse events between these two temperature management strategies. The study addresses uncertainties regarding the best temperature control after ECPR, which is a resuscitation method using ECMO to support heart and lung function during cardiac arrest. Participants receive either hypothermia treatment, where their body temperature is cooled to 33-34C using ECMO with a heat exchanger, or normothermia treatment, where the temperature is maintained at 36C. After reaching the target temperature, it is maintained for 24 hours, followed by a 24-hour rewarming period to 36-37.5C, which is then sustained until ECMO ends or for 24 hours post-rewarming. Additional treatments like sedation, muscle relaxants, antipyretics, and circulatory support may be used as needed. During the trial, participants are closely monitored for survival at discharge about 25 days, neurological function using cerebral performance categories, and adverse events during their intensive care stay approximately two weeks. Follow-up assessments occur at 30 days, 90 days, and one year after admission. The study tracks these outcomes to evaluate which temperature management approach might better support recovery after ECPR in OHCA patients.

Pancreatic cancer is often diagnosed at an advanced stage, and there is no established effective population-based screening method. This study evaluates the Enzeavour Pancreatic Cancer assay, a blood test that measures three specific enzymes at a single-molecule level and combines four biomarkers into a composite Enzeavour Score. The trial is a nationwide, multicenter, prospective, single-arm feasibility study conducted in Japan, enrolling about 10,000 asymptomatic adults. Participants undergo the Enzeavour assay during routine health checkups or organized cancer screening visits. Those with an Enzeavour Score above 0.369 are referred for further diagnostic imaging, which may include MRCP, EUS, or contrast-enhanced CT based on clinical indications. This study uses a partial verification design with 12-month follow-up for specific subgroups to estimate pancreatic cancer detection rates and positive predictive value. Throughout the study, participants provide peripheral blood samples for the assay and may undergo diagnostic imaging if their test is positive. Researchers monitor pancreatic cancer detection within 12 months after the blood draw as the primary outcome and measure the positive predictive value of the assay as a secondary outcome. The study duration extends up to the end of 2028, with safety and diagnostic results followed during this period.